Oncostatin-M ligand-based CAR-T therapy displays robust anti-tumor activity against osteosarcoma - PubMed
4 hours ago
- #CAR-T therapy
- #Osteosarcoma
- #Immunotherapy
- CAR-T therapy shows limited efficacy against solid tumors due to antigen heterogeneity.
- Oncostatin-M (OSM) ligand-based CAR-T therapy targets multiple receptors (OSMR and LIFR) in osteosarcoma.
- Osteosarcoma treatment options have remained unchanged for nearly 40 years.
- Third-generation OSM CAR-T cells demonstrated cytotoxicity against osteosarcoma in vitro and in vivo.
- OSM CAR-T cells reduced tumor burden in xenograft and metastatic mouse models.
- A new PDX model (KKOS) from a treatment-resistant osteosarcoma patient was tested successfully.
- OSM CAR-T therapy shows promise as a new treatment for osteosarcoma.